Literature DB >> 26763514

Multiple Myeloma: Diagnosis and Treatment.

S Vincent Rajkumar1, Shaji Kumar2.   

Abstract

The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26763514      PMCID： PMC5223450          DOI： 10.1016/j.mayocp.2015.11.007

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


  115 in total

1.  Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

Review 3.  Smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Ola Landgren; María-Victoria Mateos
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

6.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

8.  Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.

Authors:  Morie A Gertz; Stephen M Ansell; David Dingli; Angela Dispenzieri; Francis K Buadi; Michelle A Elliott; Dennis A Gastineau; Suzanne R Hayman; William J Hogan; David J Inwards; Patrick B Johnston; Shaji Kumar; Martha Q Lacy; Nelson Leung; Ivana N M Micallef; Luis F Porrata; Barbara A Schafer; Robert C Wolf; Mark R Litzow
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

9.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

10.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113
View more
  132 in total

1.  Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.

Authors:  Xiaobao Xie; Yan Lin; Yang Cao; Weimin Dong; Wei Wu; Yuandong Zhu; Deliang Liu; Haiqian Li; Qing Li; Weiying Gu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

2.  B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3.

Authors:  Liang Lin; Li Cao; Yang Liu; Ke Wang; Xinwei Zhang; Xiaodan Qin; Dandan Zhao; Jie Hao; Yingjun Chang; Xiaojun Huang; Bei Liu; Jun Zhang; Jin Lu; Qing Ge
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

3.  Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns.

Authors:  Aleksander Kosmala; Andreas Max Weng; Bernhard Krauss; Stefan Knop; Thorsten Alexander Bley; Bernhard Petritsch
Journal:  Eur Radiol       Date:  2018-06-07       Impact factor: 5.315

4.  Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells.

Authors:  Zhiyao Zhang; Zhenyu Li; Wenming Chen
Journal:  Exp Ther Med       Date:  2018-09-11       Impact factor: 2.447

5.  Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.

Authors:  Xinyao Li; Zhengchang He; Bingqing Cheng; Qin Fang; Dan Ma; Tingting Lu; Danna Wei; Xingyi Kuang; Sishi Tang; Jie Xiong; Jishi Wang
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

Review 6.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

7.  Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

Authors:  Archana M Rajan; S Vincent Rajkumar
Journal:  Semin Oncol       Date:  2016-11-05       Impact factor: 4.929

8.  Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.

Authors:  Bita Fakhri; Mark A Fiala; Sascha A Tuchman; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01-31

9.  Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Authors:  Saad Usmani; Tahamtan Ahmadi; Yvette Ng; Annette Lam; Avinash Desai; Ravi Potluri; Maneesha Mehra
Journal:  Oncologist       Date:  2016-08-02

10.  Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.

Authors:  Hua Yang; Xingjun Du; Yuren Xi
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.